Opportunities for U.S. biotechnology companies in Australia
CDOs – get phase I clinical trials done for less money, but with the same quality of data.
Victorian Government – local investment in R&D is incentivized with 40% cash back on the dollar.
Monash University – opening 200 bed hospital for cardiac patients, with access to world class facilities for cardiac-disease related research
Gateway to China – if trade disputes between the U.S. and China make it difficult to conduct business, it would be highly advantageous to have an Australian subsidiary. Melbourne is a hub for biotechnology in APAC – Biomelbourne network, etc.